Cascade Bio Raises $6M to Advance Cell-Free Biocatalyst Technology for Industrial Manufacturing
Key Insights
Cascade Bio (search) secured $6 million in funding, including a $2.8 million seed round and $3.2 million in NSF grants, to scale its enzyme stabilization technology for industrial biomanufacturing.
The company's "Body Armor for Enzymes" technology extends enzyme lifespan from hours to months under industrial conditions, achieving 100% success rate across 30+ enzymes for over 20 paying customers.
Cascade Bio (search)'s cell-free approach addresses key biomanufacturing challenges by eliminating microbial complexity while enabling cost-effective, scalable production across chemical, pharmaceutical, and food sectors.
Cascade Bio (search), a Denver-based industrial biotechnology company, has closed $6 million in funding to accelerate the transition from petrochemical processes to enzyme-driven manufacturing. The funding comprises a $2.8 million seed round led by Endurance28 (search), with participation from Stray Dog Capital (search), 1Flourish (search), and existing investors Range Ventures (search), Ten VC (search), and Amplify.LA (search), complemented by $3.2 million in nondilutive funding from the National Science Foundation through its cell-free ideas lab program (CFIRE) and an SBIR Phase II grant.
Revolutionary Enzyme Stabilization Technology
The company's core innovation, dubbed "Body Armor for Enzymes," utilizes cost-effective, scalable materials to dramatically extend enzyme lifespan under challenging industrial conditions. While unprotected enzymes typically lose activity within hours in industrial settings, Cascade Bio (search)'s technology maintains enzyme activity for months, representing an order of magnitude improvement in biocatalysis performance.
"Through our early-stage collaborations, we are already seeing the potential impact of our technology," said Alex Rosay, CEO and industry veteran. "We are seeing enzymes that crash out in hours maintain their activity for months. This order of magnitude improvement in biocatalysis will change the industry by dramatically improving costs and ease-of-use for nature's catalysts."
Proven Track Record with Industrial Partners
Since its founding, Cascade Bio (search) has demonstrated remarkable success across its enzyme portfolio, working on more than 30 different enzymes with a 100% success rate in improving stability under challenging industrial conditions. The company has established partnerships with over 20 paying customers, including some of the largest companies in the chemical, flavor and fragrance, food ingredient, and pharmaceutical sectors.
These early collaborations have validated the technology's ability to integrate biological processes into existing manufacturing operations while delivering meaningful cost savings. The cell-free approach addresses fundamental challenges that have limited large-scale biomanufacturing by offering rapid reaction rates, more straightforward scale-up processes, and fewer purification steps compared to traditional microbial-based systems.
Addressing Biomanufacturing Industry Challenges
The biomanufacturing sector has attracted billions in investment to transform molecule production, yet faces persistent challenges related to costs and scalability, partially due to excessive reliance on microbes with inherent complexities. By extracting enzymes from cells and ensuring their stability, Cascade Bio (search)'s approach offers an alternative path that eliminates the inefficiencies associated with microbial hosts.
The company's co-founders, Alex Rosay and James Weltz, bring combined expertise in chemical engineering and industry knowledge, drawing on experiences from Zymergen (search), Stanford (search), and CU Boulder (search). Their technical background enables the design of immobilization solutions that work across a wide range of enzyme types.
Strategic Positioning and Investor Confidence
Jared Campbell, senior partner at Endurance28 (search), expressed strong confidence in the founding team: "Alex and James represent the ideal founding partnership that Endurance28 seeks—they are 'ambitious rebels' that combine deep scientific expertise with rapid learning and unwavering commitment to their mission. We're excited to partner with founders whose technical depth and bold vision will build the platform for cell-free biocatalysis that redefines how the world makes chemicals—faster, cleaner, and more sustainable."
With headquarters in Denver and operations extending to California and New York, Cascade Bio (search) is strategically positioned to collaborate with manufacturers and lead the cell-free biomanufacturing revolution. The company's approach promises to unlock new opportunities for biobased production while addressing the complexity and expense that have historically limited industrial biotechnology adoption.